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Abstract: Pharmacologic modulation to open the K
ATP
 channels with diazoxide is useful in 
treating hyperinsulinemia. Diazoxide is being used more often in neonates with hyperinsulin-
emic hypoglycemia. This report highlights a case of severe pulmonary hypertension (PH) with 
re-opening of ductus arteriosus in an extremely premature infant after the use of diazoxide. The 
rapid onset of PH with respiratory failure was completely reversible. This case emphasizes the 
need for extreme caution with use of diazoxide in the premature infant population, especially 
those with chronic lung disease of prematurity. In addition, the use of diazoxide should be 
limited to the persistent form of congenital hyperinsulinism, after adequate work up has been 
completed to evaluate for other causes of hypoglycemia. It is postulated that development of 
PH could be related to K
ATP
 agonsim.
Keywords: hypoglycemia, hyperinsulinemia, pulmonary hypertension, diazoxide, K
ATP
 chan-
nels, ductus arteriosus
Introduction
Neonatal hypoglycemia if untreated can lead to poor neurodevelopmental outcomes.1 
Hypoglycemia is often more difficult to treat in the presence of hyperinsulinism and 
diazoxide is the only drug approved by the US Food and Drug Administration (FDA) 
to treat hyperinsulinemic hypoglycemia.1 It is generally recommended for the persistent 
form of this condition, which is often called the congenital hyperinsulinism-induced 
hypoglycemia (CHH).2 The estimated incidence of CHH in the Unites States is 1 in 
50,000 live births.3 The prevalence of its use has not been well studied, but its use in 
neonates has increased.4 Apart from diazoxide, the limited treatment options include; 
octreotide, long acting somatostatin analogs, sirolimus and surgery. There are several 
reports of diazoxide being associated with serious adverse events, which has raised 
concerns about the safety of this drug.4,5 The development of pulmonary hypertension 
(PH) with its use is a known but rare adverse event and after its initiation was observed 
in 2.4% of patients.1 This report highlights a case of severe PH with re-opening of 
ductus arteriosus in an extremely premature infant after treatment with Diazoxide.
Case report
A female infant, one of di-amniotic di-chorionic twins was born at 23-week gestation to a 
34-year-old, G3, P2, mother who had received prenatal care. The pregnancy was a product 
of in vitro fertilization. She presented in preterm labor and had a spontaneous vaginal 
delivery which was complicated by placental abruption. The baby had a birth weight of 460 
grams. The Apgar scores were 1, 1 and 6 at 1, 5 and 10 minutes respectively. She received 
one dose intra-tracheal surfactant soon after birth and did not require additional doses. 
The initial chest radiograph revealed respiratory distress syndrome along with pulmonary 
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interstitial emphysema. She was mechanically ventilated for 
three weeks followed by non-invasive ventilation for another 
five weeks. Then she needed supplemental blended nasal can-
nula oxygen at one liter per minute (LPM) with oxygen between 
22% to 26% after that and she was also on inhaled fluticasone. 
The patient had medical management of a symptomatic hemo-
dynamically significant patent ductus arteriosus from the 15th 
to the 17th day. Subsequently echocardiograms at 3 weeks, 9 
weeks and at 14 weeks of age showed that the ductus arterio-
sus remained closed and there was no evidence of pulmonary 
hypertension. The patient received parenteral nutrition for 5 
weeks till enteral feeding by orogastric and nasogastric feeding 
tube was fully established beyond that. At 12 weeks of age she 
had signs of mild cholestatic liver dysfunction and was noted 
to have intermittent hypoglycemia. The calories in her feeds 
were increased to 26 calories per ounce and her feeds had to be 
infused over an hour to manage that. Further workup with levels 
of insulin, cortisol, growth hormone, betahydroxy butyrate, free 
fatty acids, c peptide and acyl carnitine profile revealed only 
a mildly elevated insulin level. She had an adequate response 
to ACTH stimulation test but had a poor glucose response to 
glucagon administration. As the work up was interpreted as 
transient hyperinsulinism by her clinicians, she was started on 
diazoxide at 5 mg/kg/day with some improvement in blood 
glucose levels. The clinical team felt that maintaining eugly-
cemia was essential prior to sending her home and sequentially 
increased the dose by 5 mg/kg till a maximum of 15 mg /kg/
day was reached. At this point she remained euglycemic but 
her cardiorespiratory status rapidly declined. This deterioration 
was initially thought to be due to fluid retention and she was 
started on diuretics. With worsening respiratory failure and 
hypotension, she needed significant ventilator and ionotropic 
support with vasopressors. She was in FiO
2
 of 1 and after 12 
hours of conventional mechanical ventilation had to be changed 
to a high frequency oscillating ventilation. Her echocardiogram 
at 16 weeks of age (9 days after starting diazoxide) revealed 
pulmonary hypertension, tricuspid regurgitation (TR) with the 
TR jet indicating near systemic pulmonary arterial pressures, 
and a small ductus arteriosus with bidirectional flow. There 
was no evidence of right ventricular dilatation, hypertrophy 
or dysfunction. At this point her diazoxide was discontinued 
(9 days after starting). She was started on inhaled nitric oxide 
(iNO) at 20 ppm with prompt response in oxygenation and her 
FiO
2
 requirements. Her oxygenation index improved from 38 
to 27 over 4 hours and to 19 over 24 hours. She did not receive 
any additional pulmonary vasodilators. She was euglycemic, 
when maintained on intravenous alimentation. After seven days 
of mechanical ventilation, when her oxygen requirements were 
less than 50% her iNO was slowly weaned every six hours and 
she was completely off the iNO nine days after its initiation. 
Follow up echocardiograms showed that her pulmonary arte-
rial hypertension resolved over two weeks and the ductus had 
spontaneously closed. She was again weaned off mechanical 
ventilation but required nasal cannula 100% oxygen at 0.2 LPM. 
At this point she was noted to have significant cholestasis and 
hepatic dysfunction. Her liver was just palpable 1–2 cms and she 
did not have hypertriglyceridemia or lipidemia. A genetic panel 
using next generation sequencing for neonatal cholestasis and 
alpha one antitrypsin testing were negative. Her liver function 
markedly worsened necessitating a referral for liver transplant 
at the age of six months. A liver biopsy done was inconclusive 
and she succumbed while waiting for the procedure at the age 
of eight months.
Discussion
Diazoxide, like chlorothiazide, is a benzothiadiazine derivative 
and its hemodynamic effects in adults were very well described 
in the early 1960s.6 At that time, it was presumed to be an 
important treatment for primary pulmonary hypertension in 
adults.7,8 It was also noted to inhibit insulin release from the 
islet cells of the pancreas by selective inhibition of mitochon-
drial glycerol phosphate dehydrogenase.9 In addition, it also 
causes smooth muscle relaxation and fluid retention. More 
recently, it has been shown to be a potential therapeutic option 
in ion channel diseases.10–13 Opening and closing of ATP-
sensitive potassium (K
ATP
) channels are known to affect con-
tractility, cell adhesion, gap and tight junction regulation.10–13 
The K
ATP
 channels include 4 inwardly rectifying potassium 
(K
ir
) subunits and 4 sulfonylurea receptor (SUR) subunits. 
Pharmacologic modulation to open the K
ATP
 channels with 
diazoxide is useful in treating hypertension, and hyperinsu-
linemia, whereas K
ATP
 channel closers are used in the treatment 
of diabetes mellitus.10–13 Most pediatric patients receiving this 
medication were noted to develop edema and were often started 
simultaneously on diuretics.4,5 With increasing reports of PH 
developing in infants, the FDA, in 2015, issued a drug safety 
communication, warning of this association.14–17 Other cases of 
severe and life threatening complications like reopening of the 
ductus arteriosus, sepsis syndromes, heart failure, neutropenia, 
thrombocytopenia, hyperuricemia and hyperosmolar coma 
have also been reported.1,18–22 Lung biopsies done in these 
cases have shown a toxic vascular drug reaction.19 It has been 
documented that PH may be more common than previously 
recognized in premature infants.15 In infants, the incidence 
of PH could be higher as currently they do not routinely get 
echocardiogram after the initiation of the drug. The mechanism 
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of diazoxide-induced PH is unclear but direct toxic vascular 
reaction and K
ATP
 channel agonism have been postulated.19,20,23 
It is also possible that it could have a dose dependent effect on 
the PH as seen in the above case.
A small proportion of extremely preterm infants with more 
severe bronchopulmonary dysplasia (BPD) could over time 
develop PH. This case highlights the risk of development of 
secondary PH in infants treated with diazoxide, especially in 
premature infants with BPD. The sodium and fluid retention 
seen with its use contributes to the reopening of the ductus 
arteriosus and worsening any pre-existing PH. Even though it 
is reversible after cessation of therapy, PH is a life threatening 
complication. The etiology of cholestatic liver dysfunction is 
unclear as the testing was inconclusive and probably unrelated 
to the use of diazoxide. The significant deterioration in clinical 
status after its use might not have helped its resolution. This 
case is unique in that the patient had serial echocardiography 
done, as the patient’s ductus arteriosus was being monitored 
and the patient had echocardiography soon after initiation 
of treatment. Even though she was extremely preterm, she 
had mild evolving chronic lung disease (CLD), as her FiO
2
 
requirements were low and she did not have any documented 
prior evidence of PH. In addition, this adds to the body of evi-
dence on the number of patients developing PH, which would 
advocate against indiscriminate use of this drug. Extreme 
caution must be exercised in the very low birth weight infant 
and in extremely premature infants, who are at higher risk for 
development of PH secondary to CLD and its use should be 
limited to the persistent form of CHH. If diazoxide therapy is 
initiated, then serial echocardiography should be performed in 
this high risk patient population of premature infants.
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